- Home
- IMCR vs LION Comparison
IMCR vs LION Comparison
Compare IMCR & LION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- LION
- Stock Information
- Founded
- IMCR 2008
- LION 1997
- Country
- IMCR United Kingdom
- LION United States
- Employees
- IMCR N/A
- LION N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- LION Movies/Entertainment
- Sector
- IMCR Health Care
- LION Consumer Discretionary
- Exchange
- IMCR Nasdaq
- LION Nasdaq
- Market Cap
- IMCR 1.7B
- LION 2.0B
- IPO Year
- IMCR 2021
- LION N/A
- Fundamental
- Price
- IMCR $34.26
- LION $6.19
- Analyst Decision
- IMCR Buy
- LION Buy
- Analyst Count
- IMCR 9
- LION 9
- Target Price
- IMCR $57.00
- LION $8.88
- AVG Volume (30 Days)
- IMCR 287.1K
- LION 2.9M
- Earning Date
- IMCR 11-05-2025
- LION 11-06-2025
- Dividend Yield
- IMCR N/A
- LION N/A
- EPS Growth
- IMCR N/A
- LION N/A
- EPS
- IMCR N/A
- LION N/A
- Revenue
- IMCR $356,145,000.00
- LION $3,986,900,000.00
- Revenue This Year
- IMCR $29.71
- LION N/A
- Revenue Next Year
- IMCR $11.27
- LION $21.07
- P/E Ratio
- IMCR N/A
- LION N/A
- Revenue Growth
- IMCR 26.78
- LION 10.89
- 52 Week Low
- IMCR $23.15
- LION $5.55
- 52 Week High
- IMCR $39.33
- LION $8.50
- Technical
- Relative Strength Index (RSI)
- IMCR 49.34
- LION 36.84
- Support Level
- IMCR $33.92
- LION $6.61
- Resistance Level
- IMCR $37.00
- LION $7.09
- Average True Range (ATR)
- IMCR 1.45
- LION 0.26
- MACD
- IMCR -0.06
- LION -0.10
- Stochastic Oscillator
- IMCR 39.78
- LION 5.68
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About LION Lionsgate Studios Corp. Common Shares
Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.